decahydroquinoline | 10343-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉类
• 英文名称: decahydroquinoline
• 英文别名: cis-decahydroquinoline；(4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline
• CAS: 10343-99-4
• 化学式: C₉H₁₇N
• 分子量: 139.241
• InChiKey: POTIYWUALSJREP-IUCAKERBSA-N

物化性质

• 熔点：
  -40°C
• 沸点：
  245.24°C (rough estimate)
• 密度：
  0.9426

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  decahydroquinoline 在 serpentine 、 铂 作用下， 生成 5,6,7,8-四氢喹啉
  参考文献：
  名称：

  The Nitrogen Compounds in Petroleum Distillates. XXVI. Confirmation of Presence of Bz-tetrahydroquinolines in California Petroleum

  摘要：

  DOI：

  10.1021/ja01193a004
• 作为产物：
  描述：

  喹啉 在 镍 作用下， 200.0 ℃ 、19.61 MPa 条件下， 生成 decahydroquinoline
  参考文献：
  名称：

  The Nitrogen Compounds in Petroleum Distillates. XXVI. Confirmation of Presence of Bz-tetrahydroquinolines in California Petroleum

  摘要：

  DOI：

  10.1021/ja01193a004

文献信息

• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
  申请人：UNIV EDINBURGH

  公开号：WO2009074789A1

  公开（公告）日：2009-06-18

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。公式（I）。
• [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
  申请人：BIOAXONE THERAPEUTIQUE INC

  公开号：WO2005080394A1

  公开（公告）日：2005-09-01

  Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构I表示的取代哌啶化合物，其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部，可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶，并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长，从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长，并在需要Rho激酶抑制的疾病治疗中发挥作用。
• Design of New Ligands for the Palladium-Catalyzed Arylation of α-Branched Secondary Amines
  作者：Nathaniel H. Park、Ekaterina V. Vinogradova、David S. Surry、Stephen L. Buchwald

  DOI：10.1002/anie.201502626

  日期：2015.7.6

  reactions, α‐branched secondary amines are difficult coupling partners and the desired products are often produced in low yields. In order to provide a robust method for accessing N‐aryl α‐branched tertiary amines, new catalysts have been designed to suppress undesired side reactions often encountered when these amine nucleophiles are used. These advances enabled the arylation of a wide array of sterically

  在Pd催化的CN交叉偶联反应中，α支链的仲胺是困难的偶联伙伴，所需的产物通常产率较低。为了提供一种获取N-芳基α-支化叔胺的可靠方法，已设计出新的催化剂来抑制使用这些胺亲核试剂时经常遇到的不良副反应。这些进展使大量空间受限的胺芳基化，突出了合理配体设计在促进具有挑战性的Pd催化的交叉偶联反应中的重要性。
• FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180148457A1

  公开（公告）日：2018-05-31

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and R 10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是CaM激酶抑制剂，用于治疗各种疾病状态，包括心房颤动和心肌梗死。在特定实施例中，化合物的一般结构由公式I给出：其中R1、R2、R3、R4、R5、R6、R9和R10如本文所述，涉及化合物的制备和使用方法以及含有相同化合物的药物组合物。
• Herbicidal 1,2,4,6-thiatriazines
  申请人：Syngenta Investment Corporation

  公开号：US06362134B1

  公开（公告）日：2002-03-26

  Compounds of formula (I), in which R1, R2 and R3 are as defined in claim 1, are particularly suitable as herbicides.

  式（I）中的化合物，其中R1、R2和R3如权利要求1所定义，特别适用作为除草剂。